Stock Events

Stock Events

Zymeworks BC 

€21.87
49
-€0.9-3.95% Today

Statistics

Day High
22.01
Day Low
21.99
52W High
23.2
52W Low
8.05
Volume
-
Avg. Volume
-
Mkt Cap
1.64B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.68
-0.45
-0.21
0.03
Expected EPS
-0.296835
Actual EPS
N/A

Financials

-160.03%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
145.32MRevenue
-232.54MNet Income

Analyst Ratings

30.35Average Price Target
The highest estimate is 44.01.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZA8.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes in the biotechnology field, focusing on monoclonal antibodies, a key area of Zymeworks' research and development.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotech firm that develops innovative human therapeutics, including bi-specific antibodies, directly competing with Zymeworks' platforms.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is involved in the discovery, development, and commercialization of cancer treatments, competing with Zymeworks' oncology focus.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG, through its Genentech subsidiary, works on biologics for cancer, directly competing with Zymeworks in the oncology and antibody engineering space.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb Company offers a range of biopharmaceutical products, including cancer therapies that compete with Zymeworks' pipeline.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a broad portfolio including oncology products, competing with Zymeworks in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap840.84B
Eli Lilly and Company focuses on oncology and biopharmaceuticals, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc. is known for its work in antiviral drugs but also competes in the oncology space, overlapping with Zymeworks' interests.
Novartis
NVS
Mkt Cap297.35B
Novartis AG is a global healthcare company that competes with Zymeworks in the development of innovative cancer therapies.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC is involved in the discovery and development of a wide range of pharmaceutical products, including those for cancer, making it a competitor in the oncology field.

About

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Kenneth H. Galbraith C.A.
Employees
264
Country
United States
ISIN
US98985Y1082
WKN
000A3DSSN

Listings

MU
DE
ZA8.MU
STU
DE
ZA8.STU
F
DE
ZA8.F
XNAS
US
ZYME

0 Comments

Share your thoughts

FAQ

What is Zymeworks BC stock price today?▼
The current price of ZA8.F is €21.87 EUR — it has decreased by -3.95% in the past 24 hours. Watch Zymeworks BC stock price performance more closely on the chart.
What is Zymeworks BC stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zymeworks BC stocks are traded under the ticker ZA8.F.
Is Zymeworks BC stock price growing?▼
ZA8.F stock has risen by +1.81% compared to the previous week, the month change is a +10.5% rise, over the last year Zymeworks BC has showed a +171.48% increase.
What is Zymeworks BC market cap?▼
Today Zymeworks BC has the market capitalization of 1.64B
When is the next Zymeworks BC earnings date?▼
Zymeworks BC is going to release the next earnings report on May 06, 2026.
What were Zymeworks BC earnings last quarter?▼
ZA8.F earnings for the last quarter are -0.47 EUR per share, whereas the estimation was -0.39 EUR resulting in a -19.27% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Zymeworks BC revenue for the last year?▼
Zymeworks BC revenue for the last year amounts to 145.32M EUR.
What is Zymeworks BC net income for the last year?▼
ZA8.F net income for the last year is -232.54M EUR.
How many employees does Zymeworks BC have?▼
As of April 13, 2026, the company has 264 employees.
In which sector is Zymeworks BC located?▼
Zymeworks BC operates in the Health & Wellness sector.
When did Zymeworks BC complete a stock split?▼
Zymeworks BC has not had any recent stock splits.
Where is Zymeworks BC headquartered?▼
Zymeworks BC is headquartered in Middletown, United States.